These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 8766548)

  • 21. Transfer of idiotypic protein primed allogeneic marrow grafts elicits potent graft-versus-myeloma effects in mice.
    Zeis M; Steinmann J; Petrela E; Hartung G; Schmitz N; Uharek L
    Bone Marrow Transplant; 2001 Feb; 27(3):279-85. PubMed ID: 11277175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
    Colson YL; Wren SM; Schuchert MJ; Patrene KD; Johnson PC; Boggs SS; Ildstad ST
    J Immunol; 1995 Nov; 155(9):4179-88. PubMed ID: 7594573
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of tolerance to skin allografts by intrathymic injection of donor splenocytes. Effect of donor-recipient strain combination and supplemental rapamycin.
    Dono K; Maki T; Wood ML; Monaco AP
    Transplantation; 1995 Dec; 60(11):1268-73. PubMed ID: 8525521
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adenoviral transfer of a single donor-specific MHC class I gene to recipient bone marrow cells can induce specific immunological unresponsiveness in vivo.
    Fry JW; Morris PJ; Wood KJ
    Gene Ther; 2002 Feb; 9(3):220-6. PubMed ID: 11859426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunologic considerations for therapeutic strategies utilizing allogeneic hepatocytes: hepatocyte-expressed membrane-bound major histocompatibility complex class I antigen sensitizes while soluble antigen suppresses the immune response in rats.
    Scherer MN; Graeb C; Tange S; Dyson C; Jauch KW; Geissler EK
    Hepatology; 2000 Nov; 32(5):999-1007. PubMed ID: 11050050
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine.
    Anderson LD; Petropoulos D; Everse LA; Mullen CA
    Cancer Res; 1999 Apr; 59(7):1525-30. PubMed ID: 10197624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prolonged survival without posttransplant immunosuppression in a large animal model.
    Granger DK; Matas AJ; Jenkins MK; Moss AA; Chen SC; Almond PS
    Surgery; 1994 Aug; 116(2):236-41. PubMed ID: 8047990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved survival from potentially lethal graft-vs.-host disease by donor pretreatment with a recipient-specific blood transfusion. I. Requirements for induction and specificity of the effect.
    Knulst AC; Bril-Bazuin C; Tibbe GJ; Benner R
    Eur J Immunol; 1992 Oct; 22(10):2481-6. PubMed ID: 1396955
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Syngeneic bone marrow expressing a single donor class I MHC molecule permits acceptance of a fully allogeneic cardiac allograft.
    Wong W; Morris PJ; Wood KJ
    Transplantation; 1996 Nov; 62(10):1462-8. PubMed ID: 8958273
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pretransplant administration of a single donor class I major histocompatibility complex molecule is sufficient for the indefinite survival of fully allogeneic cardiac allografts: evidence for linked epitope suppression.
    Wong W; Morris PJ; Wood KJ
    Transplantation; 1997 May; 63(10):1490-4. PubMed ID: 9175815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The importance of H2 haplotype sharing in the induction of specific unresponsiveness by pretransplant blood transfusions.
    Niimi M; Roelen DL; Witzke O; van Rood JJ; Claas FH; Wood KJ
    Transplantation; 2000 Feb; 69(3):411-7. PubMed ID: 10706052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The major histocompatibility complex (MHC) of the secondary transplant tissue donor influences the cross-reactivity of alloreactive memory cells.
    Wang F; Chen J; Shao W; Kang X; Xu S; Xia J; Dai H; Peng Y; Thorlacius H; Xing J; Qi Z
    Scand J Immunol; 2011 Mar; 73(3):190-7. PubMed ID: 21204892
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recipient cells expressing single donor MHC locus products can substitute for donor-specific transfusion in the induction of transplantation tolerance when pretreatment is combined with anti-Cd4 monoclonal antibody. Evidence for a vital role of Cd4+ T cells in the induction of tolerance to class I molecules.
    Saitovitch D; Morris PJ; Wood KJ
    Transplantation; 1996 May; 61(10):1532-8. PubMed ID: 8633384
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pretransplantation blood transfusion revisited.
    van Twuyver E; Mooijaart RJ; ten Berge IJ; van der Horst AR; Wilmink JM; Kast WM; Melief CJ; de Waal LP
    N Engl J Med; 1991 Oct; 325(17):1210-3. PubMed ID: 1922208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Completely allogeneic spleen cells induced cytolytic neonatal tolerance to alloantigens, but failed to establish allo-helper interactions with host T cells.
    Ramos A; González M; López-Hoyos M; Carrió R; Merino J
    Immunology; 1996 Nov; 89(3):413-8. PubMed ID: 8958055
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD11b(+) cells in donor-specific transfusion prolonged allogenic skin graft survival through indoleamine 2,3-dioxygenase.
    Ikemoto T; Takita M; Levy MF; Shimada M; Naziruddin B
    Cell Immunol; 2013; 283(1-2):81-90. PubMed ID: 23933136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Retroviral transfer of donor MHC class I or MHC class II genes into recipient bone marrow cells can induce operational tolerance to alloantigens in vivo.
    Wong W; Billing JS; Stranford SA; Hyde K; Fry J; Morris PJ; Wood KJ
    Hum Gene Ther; 2003 Apr; 14(6):577-90. PubMed ID: 12718767
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Syngeneic bone marrow transduced with a recombinant retroviral vector to express endoplasmic reticulum signal-sequence-deleted major histocompatibility complex class-I alloantigen can induce specific immunologic unresponsiveness in vivo.
    Spriewald BM; Billing JS; Jenkins S; Wheeler P; Steger U; Bushell A; Hyde K; Morris PJ; Wood KJ
    Transplantation; 2003 Feb; 75(4):537-41. PubMed ID: 12605123
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of one-HLA-haplotype-matched and HLA-mismatched blood transfusions on recipient T lymphocyte allorepertoires.
    Young NT; Roelen DL; Iggo N; Gray DW; Roake JA; Graham V; Wood KJ; Dallman MJ; Welsh KI; Morris PJ
    Transplantation; 1997 Apr; 63(8):1160-5. PubMed ID: 9133479
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble and cell-associated forms of some yet to be identified factor in transfused blood which promotes solid tumor growth in mice.
    Okuyama M; Motoyama S; Saito S; Saito R; Nakamura M; Imano H; Minamiya Y; Ogawa J
    Surg Today; 2004; 34(8):673-7. PubMed ID: 15290397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.